secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2023-02-09T23:59:59+00:00
Accession:  0001193125-23-029167
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru reports Q1 FY2023 net loss of $36.8M; revenue falls 82% to $2.5M
---------------------------------------------------------------------

- Net revenues decreased to $2.5M from $14.1M in prior-year quarter; gross profit fell to $0.7M.
- Net loss of $36.8M ($0.46 per share) vs. $6.4M ($0.08) a year ago; operating loss $35.6M.
- Cash and equivalents dropped to $46.9M at Dec 31, 2022 from $80.2M at Sep 30, 2022.
- Sabizabulin for COVID-19 under review by FDA, EMA, MHRA, TGA, Health Canada and others.
- IDWeek data: sabizabulin showed 81.2% relative reduction in deaths in WHO 4 subset (p=0.0090).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000119312523029167/0001193125-23-029167-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000119312523029167/d458190d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-029167

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer